Decitabine Compared with Low-Dose Cytarabine for the Treatment of Older Patients with Newly Diagnosed Acute Myeloid Leukemia: A Pilot Study of Safety, Efficacy, and Cost-Effectiveness

Table 3

Comparison of outcome, excluding induction mortality subjects.

Outcome	Decitabine ()	Low-dose cytarabine ()
Overall survival (in months), excluding induction mortality subjects
Median	6	5.5
Range	(1.5–13)	(4.0–17.10)
Mean survival time	6.12	7.13
Testing equality of survival distribution
Log-rank test, value	0.5311
Hazard ratio (95% Wald confidence interval)	0.786 (0.357–1.731)